Evidence map›Paper›PMID 37866772›Full record

ArticleChest2024

Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis.

John S Kim, Shwu-Fan Ma, Jennie Z Ma, Yong Huang, Catherine A Bonham, Justin M Oldham, Ayodeji Adegunsoye, Mary E Strek, Kevin R Flaherty, Emma Strickland and 5 more

Open access · greenAbstract read
In one paragraph

Article in Chest, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

John S KimDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA; Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. Electronic address: Jk6jb@virginia.edu.
Shwu-Fan MaDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
Jennie Z MaDepartment of Public Health, University of Virginia School of Medicine, Charlottesville, VA.
Yong HuangDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
Catherine A BonhamDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
Justin M OldhamDepartment of Medicine, University of Michigan, Ann Arbor, MI.
Ayodeji AdegunsoyeDepartment of Medicine, University of Chicago, Chicago, IL.
Mary E StrekDepartment of Medicine, University of Chicago, Chicago, IL.
Kevin R FlahertyDepartment of Medicine, University of Michigan, Ann Arbor, MI.
Emma StricklandDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
Inemesit UdofiaDepartment of Medicine, University of Chicago, Chicago, IL.
Joshua J MooneyDepartment of Medicine, Stanford University, Palo Alto, CA.
Shrestha GhoshDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Immunology, Harvard Medical School, Boston, MA.
Krishnarao MaddipatiDepartment of Pathology, Wayne State University, Detroit, MI.
Imre NothDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
University of Virginia · USUniversity of Chicago · USUniversity of Michigan · USHarvard University · USStanford University · USWayne State University · US

Funding

Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
Role of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
Triple Quadrupole - Ion Trap Hybrid LC/MS/MS SystemS10RR027926 · NCRR · WAYNE STATE UNIVERSITY · PI MADDIPATI, KRISHNARAO · 2010 to 2010
$425k
NCRR NIH HHS S10 RR027926NHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23 HL150301NHLBI NIH HHS R01 HL169166
6 · The paper itself

Abstract

backgroundPreclinical experiments suggest protective effects of omega-3 fatty acids and their metabolites in lung injury and fibrosis. Whether higher intake of omega-3 fatty acids is associated with disease progression and survival in humans with pulmonary fibrosis is unknown. RESEARCH QUESTION: What are the associations of plasma omega-3 fatty acid levels (a validated marker of omega-3 nutritional intake) with disease progression and transplant-free survival in pulmonary fibrosis? STUDY DESIGN AND

methodsOmega-3 fatty acid levels were measured from plasma samples of patients with clinically diagnosed pulmonary fibrosis from the Pulmonary Fibrosis Foundation Patient Registry (n = 150), University of Virginia (n = 58), and University of Chicago (n = 101) cohorts. The N-3 index (docosahexaenoic acid + eicosapentaenoic acid) was the primary exposure variable of interest. Linear-mixed effects models with random intercept and slope were used to examine associations of plasma omega-3 fatty acid levels with changes in FVC and diffusing capacity for carbon monoxide over a period of 12 months. Cox proportional hazards models were used to examine transplant-free survival. Stratified analyses by telomere length were performed in the University of Chicago cohort.

resultsMost of the cohort were patients with idiopathic pulmonary fibrosis (88%) and male patients (74%). One-unit increment in log-transformed N-3 index plasma level was associated with a change in diffusing capacity for carbon monoxide of 1.43 mL/min/mm Hg per 12 months (95% CI, 0.46-2.41) and a hazard ratio for transplant-free survival of 0.44 (95% CI, 0.24-0.83). Cardiovascular disease history, smoking, and antifibrotic usage did not significantly modify associations. Omega-3 fatty acid levels were not significantly associated with changes in FVC. Higher eicosapentaenoic acid plasma levels were associated with longer transplant-free survival among University of Chicago participants with shorter telomere length (P value for interaction = .02).

interpretationFurther research is needed to investigate underlying biological mechanisms and whether omega-3 fatty acids are a potential disease-modifying therapy.

Indexed as

Fatty Acids, Omega-3Idiopathic Pulmonary FibrosisCarbon MonoxideDisease ProgressionEicosapentaenoic AcidHumansMaleCarbon MonoxideEicosapentaenoic AcidFatty Acids, Omega-3omega-3 fatty acidspulmonary fibrosistelomere length

Identifiers

PMID37866772
PMCPMC10925547
OpenAlexW4387807647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.